Hepatotoxicity induced by alendronate therapy

[1]  J. Suzuki,et al.  Osteonecrosis of the jaw and oral bisphosphonate treatment. , 2006, Journal of the American Dental Association.

[2]  N. Maalouf,et al.  Bisphosphonate-induced hypocalcemia: report of 3 cases and review of literature. , 2006, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[3]  James H. Lewis,et al.  Drug-induced liver disease. , 2003, Current opinion in gastroenterology.

[4]  C. Coleman,et al.  Alendronate‐Induced Auditory Hallucinations and Visual Disturbances , 2004, Pharmacotherapy.

[5]  R. Rizzoli,et al.  Upper gastrointestinal and overall tolerability of alendronate once weekly in patients with osteoporosis: results of a randomized, double-blind, placebo-controlled study * , 2004, Current medical research and opinion.

[6]  S. Greenspan,et al.  Tolerability of once-weekly alendronate in patients with osteoporosis: a randomized, double-blind, placebo-controlled study. , 2002, Mayo Clinic proceedings.

[7]  J. D. Jaureguiberry,et al.  Hépatite aiguë sévère imputable à l'alendronate , 2002 .

[8]  J. D. de Jauréguiberry,et al.  [Severe acute hepatitis induced by alendronate]. , 2002, Gastroenterologie clinique et biologique.

[9]  M. Arribas,et al.  Lesión hepatocelular inducida por alendronato , 2001 .

[10]  C. de la Serna Higuera,et al.  [Alendronate-induced hepatocellular lesion]. , 2001, Gastroenterologia y hepatologia.

[11]  J. Azuri,et al.  Liver damage due to alendronate. , 2000, The New England journal of medicine.

[12]  J. Lewis.  Drug‐induced liver disease , 1990, The Medical clinics of North America.

[13]  D. Felsenberg,et al.  Multinational, Placebo-Controlled, Randomized Trial of the Effects of Alendronate on Bone Density and Fracture Risk in Postmenopausal Women with Low Bone Mass: Results of the FOSIT Study , 1999, Osteoporosis International.

[14]  N. Watts,et al.  The clinical tolerability profile of alendronate. , 1999, International journal of clinical practice. Supplement.

[15]  G. Rodan,et al.  Preclinical safety profile of alendronate. , 1999, International journal of clinical practice. Supplement.

[16]  K. Kaneda,et al.  A Double-Masked Multicenter Comparative Study Between Alendronate and Alfacalcidol in Japanese Patients with Osteoporosis , 1999, Osteoporosis International.

[17]  R. Lieverse.  Hepatitis after alendronate. , 1998, The Netherlands journal of medicine.

[18]  D. Felsenberg,et al.  Placebo-controlled multicenter study of oral alendronate in postmenopausal osteoporotic women. FOSIT-Study-Group. Fosamax International Trial. , 1998, Maturitas.

[19]  A. P. Ferrari Júnior,et al.  Esophageal ulcer and alendronate. , 1998, Sao Paulo medical journal = Revista paulista de medicina.

[20]  D. Sigulem,et al.  Risk factors for protein-energy malnutrition in pre-school shantytown children in São Paulo, Brazil. , 1998, Sao Paulo medical journal = Revista paulista de medicina.

[21]  J H Lewis,et al.  Drug-induced liver disease. , 2000, Clinics in liver disease.